ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1703

Obesity Is Related with Active State in Psoriatic Arthritis and Rheumatoid Arthritis but Not Ankylosing Spondylitis at Real Life Biological Cohort

Umut Kalyoncu, Levent Kilic, Abdulsamet Erden, Alper Sari, Berkan Armagan, Omer Karadag, Ali Akdogan, Sule Apras Bilgen and Ihsan Ertenli, Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Obesity and rheumatic disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Adipose
tissue and adipokines are linked to inflammation. The relationship of obesity
to rheumatologic disease activity is complex and recent studies demonstrate a connection
(1-3). Our objective was to assess association of disease activity with obesity
in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic
arthritis (PsA) in a single center biological registry.

Methods:
Hacettepe University Rheumatology Biological database is a single center
registry, including 1015 RA, 814 AS and 203 PsA patients on biologics. Collected
data include demographics, 28 tender/swollen joint counts, 100mm visual analog
scale (VAS) for patient global assessment (PtGA), fatigue, pain, ESR, CRP,
health assessment questionnaire (HAQ), Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI),
PsAID-12 and DAS-28.  BMI was recorded before anti-TNF treatments. BMI≥30
was defined as obesity. We used the following cut-offs to dichotomize groups:  DAS28>3.2,
BASDAI>4, BASFI>4, PSAID>4, HAQ>0.5, SJC≥1, TJC≥1, for PtGA/BASDAI/BASFI/Fatigue/Pain>40
mm, ESR and CRP>ULN.

Results:
There were 655 RA (79.1%F), 624 AS (33.5% F) and 161 PsA (65.8%F), patients. Mean(SD)
age was 52.8 (12.5) 41.8 (11.4) and 44.8 (11.8) years. Mean(SD) disease
duration was 11.5 (8.0), 10.1(7.5) and 10.3(7.3) years. In RA, AS and PsA mean(SD)
 BMI was 29.1 (5.9), 27.2 (5.4), 28.7 (6.1); and %BMI>30 were 40.2, 24.5 and
37.3.  Disease activity groups by BMI categories are shown in Table.

Conclusion:
In
these cross sectional view, obese RA (DAS-28, all PROs, acute phase reactants)
and PsA (BASDAI, PsAID, pain) patients had more active state, however obesity
did not influence on activity of AS patients. Functional impairment of obese
patients may be related mechanical effect of weight rather than disease
activity. For each disease, different influence of BMI on disease activities
need to assess at other biological registries.   

References:

1.   
Sandberg
ME et al. Ann Rheum Dis. 2014;73:2029-33.

2.   
Durcan
L et al. J Rheumatol. 2012;39:2310-4.

3.   
Eder
L et al. Ann Rheum Dis. 2015;74:813-7.

Table. Disease activity and
patient reported measures by BMI categories

 

Measures

Diagnosis

BMI≥30

BMI<30

p-value

DAS-28 > 3.2

n (%)

RA

135/247 (54.6)

159/365(43.6)

0.007

AS

NA

NA

NA

PsA

24/46 (52.2)

33/82 (40.2)

0.19

BASDAI > 4

n (%)

RA

NA

NA

NA

AS

46/152 (30.3)

126/429 (29.4)

0.41

PsA

38/60 (63.3)

35/99 (35.3)

0.001

BASFI>4

n (%)

RA

NA

NA

NA

AS

53/151 (35.1)

108/467 (23.1)

0.004

PsA

28/60 (46.7)

26/99 (26.3)

0.008

PsAID>4

n (%)

RA

NA

NA

NA

AS

NA

NA

NA

PsA

40/60 (66.7)

44/101 (43.6)

0.005

HAQ > 0.5

n (%)

RA

155/253 (61.3)

166/371 (44.7)

<0.001

AS

NA

NA

NA

PsA

32/60 (53.3)

40/100 (40.0)

0.10

SJC ≥ 1

n (%)

RA

116/252 (46.0)

150/372 (40.3)

0.16

AS

3/136 (2.2)

13/415 (3.1)

0.58

PsA

13/48 (27.1)

25/88 (28.4)

0.87

TJC ≥ 1

n (%)

RA

165/252 (65.5)

216/372 (58.1)

0.062

AS

9/137 (6.6)

23/415 (5.5)

0.65

PsA

21/48 (43.7)

35/88 (39.8)

0.65

PtGA > 40 mm

n (%)

RA

146/255 (57.2)

177/382 (46.3)

0.007

AS

52/153 (33.9)

155/471 (32.9)

0.81

PsA

35/60 (58.3)

44/100 (44.0)

0.079

Pain > 40 mm

n (%)

RA

152/256 (59.3)

182/383 (47.5)

0.003

AS

50/150 (33.3)

165/463 (21.6)

0.61

PsA

38/59 (64.4)

47/99 (47.5)

0.039

Fatigue > 40 mm

n (%)

RA

156/256 (60.9)

186/283 (65.7)

0.002

AS

56/150 (37.3)

157/463 (33.9)

0.44

PsA

38/59 (64.4)

49/99 (49.5)

0.068

CRP > ULN

n (%)

RA

113/248 (45.6)

124/359 (34.5)

0.006

AS

65/143 (45.5)

160/438 (36.5)

0.057

PsA

23/56 (41.1)

37/91 (40.6)

0.96

ESR > ULN

n (%)

RA

122/255 (47.8)

115/371 (30.9)

<0.001

AS

38/148 (25.7)

101/455 (22.2)

0.38

PsA

22/56 (39.3)

28/92 (30.4)

0.27

 


Disclosure: U. Kalyoncu, None; L. Kilic, None; A. Erden, None; A. Sari, None; B. Armagan, None; O. Karadag, None; A. Akdogan, None; S. Apras Bilgen, None; I. Ertenli, None.

To cite this abstract in AMA style:

Kalyoncu U, Kilic L, Erden A, Sari A, Armagan B, Karadag O, Akdogan A, Apras Bilgen S, Ertenli I. Obesity Is Related with Active State in Psoriatic Arthritis and Rheumatoid Arthritis but Not Ankylosing Spondylitis at Real Life Biological Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/obesity-is-related-with-active-state-in-psoriatic-arthritis-and-rheumatoid-arthritis-but-not-ankylosing-spondylitis-at-real-life-biological-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-is-related-with-active-state-in-psoriatic-arthritis-and-rheumatoid-arthritis-but-not-ankylosing-spondylitis-at-real-life-biological-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology